Slow-growing thalamic glioma with H3 K27M mutation: 3-year follow-up before surgical intervention.

There are currently no effective therapeutic options for the treatment of DMG-K27M. The slow tumor growth and prolonged survival time (≥3 years) in the absence of intervention seen here serve as a reminder that much is still not known about H3 K27M mutation and how it impacts the pathophysiology, diagnosis, treatment, and prognosis of the disease. Careful evaluation should be done to determine if early intervention is the best approach when treating DMG-K27M.